Soleno Therapeutics (SLNO) Current Assets (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Current Assets data on file, last reported at $326.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 5.65% year-over-year to $326.4 million in Q1 2026; TTM through Mar 2026 was $326.4 million, a 5.65% increase from a year earlier, with the FY2025 full-year figure at $355.8 million, up 21.07% from the prior year.
• Current Assets for Q1 2026 stood at $326.4 million, down from $355.8 million in the prior quarter.
• Over the last five years, Current Assets for SLNO reached as high as $534.9 million in Q3 2025 and fell as low as $9.1 million in Q1 2023.
• Historically, Current Assets has averaged $185.8 million across 5 years, with a median of $171.4 million in 2023.
• Across the five-year window, Current Assets tumbled 69.55% in 2023 and soared 1556.88% in 2024, its largest moves.
• Year by year, Current Assets stood at $15.6 million in 2022, then surged by 995.15% to $171.4 million in 2023, then soared by 71.51% to $293.9 million in 2024, then rose by 21.07% to $355.8 million in 2025, then dropped by 8.27% to $326.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $326.4 million in Q1 2026, $355.8 million in Q4 2025, and $534.9 million in Q3 2025.